Mo Zhou
Sun Yat-sen University
12 Papers
Mo Zhou is an academic researcher from Sun Yat-sen University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
CBX4 contributes to HIV‐1 latency by forming phase‐separated nuclear bodies and SUMOylating EZH2
Liyang Wu,Ting Pan,Mo Zhou,Tao Chen,Shiyue Wu,Xi Lv,Jun Lu,Fei Yu,Yuanjun Guan,Bingfeng Liu,Wanying Zhang,Xiao Jie Deng,Anqi Liang,Yingtong Lin,Lili Wang,Xiaoping Tang,Weiping Cai,Linghua Li,Xin He,Hui Zhang,Xiancai Ma +20 more
TL;DR: It is found that CBX4, a component of the Polycomb Repressive Complex 1 (PRC1), contributes to HIV‐1 latency in seven latency models and primary CD4+ T cells and Dissolution of phase‐separatedCBX4 bodies could be a potential intervention to reactivate latent HIV‐ 1.
25
Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment
Baijin Xia,Keming Lin,Xuemei Wang,Feili Chen,Mo Zhou,Yuzhuang Li,Yingtong Lin,Yidan Qiao,Rong Li,Wanying Zhang,Xin He,Fan Zou,Linghua Li,Lijuan Lu,Cancan Chen,Wenyu Li,Hui Zhang,Bingfeng Liu +17 more
- 01 Jul 2023
TL;DR: This work constructed an alpaca nanobody (Nb) phage library and generated high-affinity and -specificity Nbs targeting CD30 and CD5, respectively, and demonstrated that Nb-derived bispecific CAR-T cells significantly improved anti-tumor efficacy in TCL treatment.
11
The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments
Tao Chen,Jieyi Deng,Yongli Zhang,Bingfeng Liu,Ruxin Liu,Yiqiang Zhu,Mo Zhou,Yingtong Lin,Baijin Xia,Keming Lin,Xiancai Ma,Hui Zhang +11 more
TL;DR: Researchers developed modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalently linking allogeneic T cells with antibody fragments, enabling targeted eradication of HIV-1-infected cells and T lymphoma cells with improved efficiency and reduced alloreactivity.
6
Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology
Keming Lin,Baijin Xia,Xuemei Wang,Xin He,Mo Zhou,Yingtong Lin,Yidan Qiao,Rong Li,Qier Chen,Yuzhuang Li,Jinzhu Feng,Tao Chen,Cancan Chen,Xinyu Li,Hui Zhang,Lijuan Lu,Bingfeng Liu,Xu Zhang +17 more
TL;DR: An exploration of FGFR4 in the field of Nb-derived CAR-T cell therapy for HCC, holding promise for enhancing safety and effectiveness in the clinical treatment of HCC in the future.
3
Identification of CD98 as a Novel Biomarker for HIV-1 Permissiveness and Latent Infection
Wanying Zhang,Mo Zhou,Cancan Chen,Shiyue Wu,Lili Wang,Baijin Xia,Jun Lu,Xiancai Ma,Ting Pan,Hui Zhang,Linghua Li,Bingfeng Liu +11 more
TL;DR: This study demonstrates that CD98 can be used as a novel biomarker of HIV-1 latently infected cells to indicate the effect of various strategies to reduce the viral reservoir.
2